Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MGUUX
ADC Name
FDA-022
Synonyms
FDA 022; FDA-022
   Click to Show/Hide
Organization
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
Antibody Name
Undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Topoisomerase I inhibitor
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05564858
Phase 1
A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05564858  Clinical Status Phase 1
Clinical Description A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors.
References
Ref 1 A PhaseStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors, NCT05564858

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.